The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Steatosis: Co-factor in Other Liver Diseases *
Open accessAbstract
The prevalence of fatty liver is rising in association with the global increase in obesity and type 2 diabetes. In the past, simple steatosis was regarded as benign, but the presence of another liver disease may provide a synergistic combination of steatosis, cellular adaptation, and oxidative damage that aggravates liver injury. In this review, a major focus is on the role of steatosis as a co-factor in chronic hepatitis C (HCV), where the mechanisms promoting fibrosis and the effect of weight reduction in minimizing liver injury have been most widely studied. Steatosis, obesity, and associated metabolic factors may also modulate the response to alcohol- and drug-induced liver disease and may be risk factors for the development of hepatocellular cancer. The pathogenesis of injury in obesity-related fatty liver disease involves a number of pathways, which are currently under investigation. Enhanced oxidative stress, increased susceptibility to apoptosis, and a dysregulated response to cellular injury have been implicated, and other components of the metabolic syndrome such as hyperinsulinemia and hyperglycemia are likely to have a role. Fibrosis also may be increased as a by-product of altered hepatocyte regeneration and activation of bipotential hepatic progenitor cells. In conclusion , active management of obesity and a reduction in steatosis may improve liver injury and decrease the progression of fibrosis. (Hepatology 2005;42:5–13.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
Self-citationBugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice
Moriya, K., Fujie, H., Shintani, Y., Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K., Matsuura, Y., Kimura, S., Miyamura, T., & Koike, K. (1998) · Nature Medicine · doi:10.1038/2053 · Cited by 1,206
Genomic analysis of the host response to hepatitis C virus infection
Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608199 · Cited by 1,161
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085
Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M.-F., Utili, R., & Ruggiero, G. (2001) · Hepatology · doi:10.1053/jhep.2001.24432 · Cited by 1,059
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Cited by
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationNonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2009) · Hepatology · doi:10.1002/hep.22742 · Cited by 1,997
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Directed differentiation of human embryonic stem cells into functional hepatic cells†
Cai, J., Zhao, Y., Liu, Y., Ye, F., Song, Z., Qin, H., Meng, S., Chen, Y., Zhou, R., Song, X., et al. (2007) · Hepatology · doi:10.1002/hep.21582 · Cited by 634
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., & Serrano, M. (2010) · Nature Communications · doi:10.1038/ncomms1001 · Cited by 612
A Human Hepatocellular in Vitro Model to Investigate Steatosis
Gómez-Lechón, M. J., Donato, M. T., Martínez-Romero, A., Jiménez, N., Castell, J. V., & O’Connor, J.-E. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.004 · Cited by 576
Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia–Brandt, L., Colloredo, G., Adinolfi, L. E., Asselah, T., Jonsson, J. R., Smedile, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.014 · Cited by 565
Self-citationRichardson, M. M., Jonsson, J. R., Powell, E. E., Brunt, E. M., Neuschwander–Tetri, B. A., Bhathal, P. S., Dixon, J. B., Weltman, M. D., Tilg, H., Moschen, A. R., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.012 · Cited by 482
Self-citationLuo, X., Li, H., Ma, L., Zhou, J., Guo, X., Woo, S.-L., Pei, Y., Knight, L. R., Deveau, M., Chen, Y., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.010 · Cited by 415
Redox mechanisms in hepatic chronic wound healing and fibrogenesis
Novo, E., & Parola, M. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-5 · Cited by 406
GI Epidemiology: nonalcoholic fatty liver disease
ANGULO, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03246.x · Cited by 369
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100403 · Cited by 357
From NAFLD in clinical practice to answers from guidelines
Nascimbeni, F., Pais, R., Bellentani, S., Day, C. P., Ratziu, V., Loria, P., & Lonardo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.044 · Cited by 337
Alcohol effects on hepatic lipid metabolism
Jeon, S., & Carr, R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.r119000547 · Cited by 326
Chitturi, S., Farrell, G. C., Hashimoto, E., Saibara, T., Lau, G. K., Sollano, J. D., & NAFLD, T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05001.x · Cited by 312
McCormack, L., Petrowsky, H., Jochum, W., Furrer, K., & Clavien, P.-A. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251747.80025.b7 · Cited by 309
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 306
Oxidative mechanisms in the pathogenesis of alcoholic liver disease
Albano, E. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.09.004 · Cited by 302
Histological assessment of non‐alcoholic fatty liver disease
Hübscher, S. G. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02416.x · Cited by 292
Estimation of Hepatic Proton-Density Fat Fraction by Using MR Imaging at 3.0 T
Yokoo, T., Shiehmorteza, M., Hamilton, G., Wolfson, T., Schroeder, M. E., Middleton, M. S., Bydder, M., Gamst, A. C., Kono, Y., Kuo, A., et al. (2011) · Radiology · doi:10.1148/radiol.10100659 · Cited by 290
Webb, M., Yeshua, H., Zelber-Sagi, S., Santo, E., Brazowski, E., Halpern, Z., & Oren, R. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.07.4016 · Cited by 285
Sasso, M., Miette, V., Sandrin, L., & Beaugrand, M. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.08.001 · Cited by 283
Kim, K. H., Shin, H., Kim, K., Choi, H. M., Rhee, S. H., Moon, H., Kim, H. H., Yang, U. S., Yu, D., & Cheong, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.039 · Cited by 281
Hepatic Microcirculation in Fatty Liver Disease
Farrell, G. C., Teoh, N. C., & Mccuskey, R. S. (2008) · The Anatomical Record · doi:10.1002/ar.20715 · Cited by 266
Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.063 · Cited by 248
Pathogenesis of alcohol‐induced liver disease: Classical concepts and recent advances
Seth, D., Haber, P. S., Syn, W., Diehl, A. M., & Day, C. P. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06756.x · Cited by 166
Pregnane X receptor is essential for normal progression of liver regeneration†
Dai, G., He, L., Bu, P., & Wan, Y. Y. (2008) · Hepatology · doi:10.1002/hep.22129 · Cited by 114
HBx-Induced Hepatic Steatosis and Apoptosis Are Regulated by TNFR1- and NF-κB-Dependent Pathways
Kim, J. Y., Song, E. H., Lee, H. J., Oh, Y. K., Choi, K.-H., Yu, D.-Y., Park, S. I., Seong, J.-K., & Kim, W.-H. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.02.016 · Cited by 71
Metadata
- Authors
- Powell, E. E., Jonsson, J. R., & Clouston, A. D.
- Venue
- Hepatology
- Published
- 2005-07
- Volume
- 42
- Issue
- 1
- Pages
- 5-13
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2164778116
- Cited by
- 374
- References
- 95
- FWCI
- 24.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.